Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joe Ciaffoni | $680,114 | $0 | $15,319,404 | $0 | $2,100,000 | $0 | $401,696 | $18,501,214 |
| Chief Executive Officer | ||||||||
| Pat Barry | 408,333 | 300,000 | 3,247,375 | 0 | 840,000 | 0 | 110,036 | 4,905,744 |
| Chief Commercial Officer | ||||||||
| Christian Heidbreder | 652,628 | 0 | 2,689,676 | 0 | 783,154 | 0 | 57,090 | 4,182,548 |
| Chief Scientific Officer | ||||||||
| Richard Simkin | 325,008 | 0 | 2,968,661 | 0 | 448,778 | 0 | 274,869 | 4,017,316 |
| Former Chief Commercial Officer | ||||||||
| Ryan Preblick | 558,820 | 0 | 2,303,067 | 0 | 670,584 | 0 | 59,922 | 3,592,393 |
| Chief Financial Officer | ||||||||
| Jeff Burris | 569,001 | 0 | 2,337,861 | 0 | 569,000 | 0 | 45,353 | 3,521,215 |
| Chief Legal Officer | ||||||||
| Mark Crossley | 902,261 | 0 | 162,518 | 0 | 2,054,522 | 0 | 66,290 | 3,185,591 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Joe Ciaffoni | $18,501,214 | — | — | — |
| Pat Barry | 4,905,744 | — | — | — |
| Christian Heidbreder | 4,182,548 | 2,506,997 | 2,852,128 | +1,675,551 |
| Richard Simkin | 4,017,316 | 3,185,460 | 3,616,813 | +831,856 |
| Ryan Preblick | 3,592,393 | 2,281,564 | 2,397,132 | +1,310,829 |
| Jeff Burris | 3,521,215 | 1,969,776 | 2,202,090 | +1,551,439 |
| Mark Crossley | 3,185,591 | 3,853,518 | 4,391,241 | −667,927 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Pat Barry | RSU | 2025-06-02 | — | — | 130,312 | — | — |
| Pat Barry | PSU | 2025-06-02 | 65,156 | 130,312 | — | 260,624 | 1,623,688 |
| Jeff Burris | PSU | 2025-03-07 | 83,701 | 167,401 | — | 334,802 | 1,451,367 |
| Jeff Burris | PSU | 2025-09-30 | — | — | — | — | 73,406 |
| Jeff Burris | RSU | 2025-03-07 | — | — | 71,743 | — | 695,907 |
| Jeff Burris | PSU | 2025-09-30 | — | — | — | — | 117,181 |
| Joe Ciaffoni | RSU | 2025-05-13 | — | — | 422,302 | — | 4,687,552 |
| Joe Ciaffoni | PSU | 2025-05-13 | 380,072 | 380,072 | — | 1,266,903 | 10,631,851 |
| Mark Crossley | PSU | 2025-09-30 | — | — | — | — | 71,768 |
| Mark Crossley | RSU | 2025-03-14 | — | — | 9,375 | — | 90,750 |
| Christian Heidbreder | PSU | 2025-09-30 | — | — | — | — | 134,403 |
| Christian Heidbreder | RSU | 2025-03-07 | — | — | 82,287 | — | 798,184 |
| Christian Heidbreder | PSU | 2025-03-07 | 96,002 | 192,004 | — | 384,008 | 1,664,675 |
| Christian Heidbreder | PSU | 2025-09-30 | — | — | — | — | 92,415 |
| Ryan Preblick | PSU | 2025-03-07 | — | — | — | — | 1,425,400 |
| Ryan Preblick | RSU | 2025-03-07 | — | — | 70,459 | — | 683,452 |
| Ryan Preblick | PSU | 2025-09-30 | 82,203 | 164,406 | — | 328,812 | 115,084 |
| Ryan Preblick | PSU | 2025-09-30 | — | — | — | — | 79,131 |
| Richard Simkin | PSU | 2025-03-07 | 114,741 | 229,482 | — | 458,964 | 1,989,609 |
| Richard Simkin | PSU | 2025-09-30 | — | — | — | — | 25,595 |
| Richard Simkin | PSU | 2025-09-30 | — | — | — | — | 2,462 |
| Richard Simkin | RSU | 2025-03-07 | — | — | 98,350 | — | 953,995 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Pat Barry | $0 | $1,623,688 | $0 | 100.0% |
| Jeff Burris | 695,907 | 1,641,954 | 0 | 70.2% |
| Joe Ciaffoni | 4,687,552 | 10,631,851 | 0 | 69.4% |
| Mark Crossley | 90,750 | 71,768 | 0 | 44.2% |
| Christian Heidbreder | 798,184 | 1,891,493 | 0 | 70.3% |
| Ryan Preblick | 683,452 | 1,619,615 | 0 | 70.3% |
| Richard Simkin | 953,995 | 2,017,666 | 0 | 67.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Joe Ciaffoni | PSU | 1,266,903 | — | $45,456,480 |
| Joe Ciaffoni | RSU | 422,302 | — | 15,152,196 |
| Christian Heidbreder | PSU | 192,004 | — | 6,889,104 |
| Jeff Burris | PSU | 167,401 | — | 6,006,348 |
| Mark Crossley | PSU | 157,732 | — | 5,659,424 |
| Mark Crossley | RSU | 140,385 | — | 5,037,014 |
| Pat Barry | RSU | 130,312 | — | 4,675,595 |
| Pat Barry | PSU | 130,312 | — | 4,675,595 |
| Christian Heidbreder | PSU | 114,092 | — | 4,093,621 |
| Christian Heidbreder | RSU | 101,544 | — | 3,643,399 |
| Ryan Preblick | PSU | 164,406 | — | 3,505,189 |
| Richard Simkin | RSU | 90,692 | — | 3,254,033 |
| Jeff Burris | PSU | 90,625 | — | 3,251,625 |
| Ryan Preblick | RSU | 86,949 | — | 3,119,730 |
| Christian Heidbreder | RSU | 82,287 | — | 2,952,458 |
| Jeff Burris | RSU | 79,893 | — | 2,866,561 |
| Jeff Burris | RSU | 71,743 | — | 2,574,139 |
| Ryan Preblick | RSU | 70,459 | — | 2,528,069 |
| Richard Simkin | PSU | 55,790 | — | 2,001,745 |
| Richard Simkin | PSU | 17,588 | — | 631,057 |
| Mark Crossley | RSU | 16,959 | — | 608,489 |
| Mark Crossley | RSU | 9,375 | — | 336,375 |
| Ryan Preblick | RSU | 6,302 | — | 226,116 |
Indivior follows a pay-for-performance and market-competitive philosophy intended to drive business results and maximize shareholder value. Compensation is highly incentive-based and heavily weighted towards long-term awards to emphasize long-term performance and support retention.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer (US) LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-13 | 90,364,566 | 1,324,996 | 1,248,134 | 98.55% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-13 | 98.55%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David WheadonIndependent | $441,027 | — | — | — | — | $441,027 |
| Juliet ThompsonIndependent · Audit (Chair) · Compliance & Ethics · Nominating & Corporate Governance | 251,563 | — | — | — | — | 251,563 |
| Barbara RyanIndependent · Audit · Compensation (Chair) · Nominating & Corporate Governance | 220,466 | — | — | — | — | 220,466 |
| Mark StejbachIndependent · Audit · Compliance & Ethics (Chair) · Science | 217,511 | — | — | — | — | 217,511 |
| Keith HumphreysIndependent | 196,785 | — | — | — | — | 196,785 |
| Daniel NinivaggiIndependent · Compensation · Nominating & Corporate Governance (Chair) · Newly elected | 186,697 | — | — | — | — | 186,697 |
| Tony KingsleyIndependent · Audit · Compensation · Newly elected | 140,000 | — | — | — | — | 140,000 |
| Jo LeCouilliardIndependent · Not standing for re-election | 42,035 | — | — | — | — | 42,035 |
| Peter BainsIndependent · Not standing for re-election | 39,920 | — | — | — | — | 39,920 |
| Robert SchriesheimIndependent · Departed during FY | 19,606 | — | — | — | — | 19,606 |
| Joe CiaffoniEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 30,000 / 20,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,755,610 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $1,755,610 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Indivior Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Indivior Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 4 | Indivior Pharmaceuticals | 2025 | Joe Ciaffoni | 680,114 | 15,319,404 | 0 | 2,100,000 | 18,501,214 |
| 5 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 6 | Exact Sciences Corporation | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 7 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 8 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 9 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 10 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 11 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 12 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 13 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 14 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 15 | Novavax, Inc. | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 16 | Amneal Pharmaceuticals, Inc. | 2025 | Chirag Patel | 800,000 | 6,974,995 | 0 | 848,000 | 8,691,745 |
| 17 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 18 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 19 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 20 | Emergent BioSolutions Inc. | 2025 | Joseph Papa | 1,037,385 | 1,638,500 | 1,191,500 | 1,446,640 | 5,321,147 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Indivior Pharmaceuticals | not disclosed | PSU 70 · RSU 30 | not disclosed | Mercer (US) LLC |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | FW Cook |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
| Amneal Pharmaceuticals, Inc. | 106% | PSU 65 · RSU 35 | No | Meridian |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Corcept Therapeutics Incorporated | 100% | not disclosed | not disclosed | not disclosed |
| Emergent BioSolutions Inc. | 107% | Options 50 · PSU 50 | No | Willis Towers Watson |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Intra-Cellular Therapies, Inc. | 150% | RSU 75 · PSU 25 | Yes — Total Stockholder Return (TSR) relative to Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals, Inc. | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Neurocrine Biosciences, Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Novavax, Inc. | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Pacira BioSciences, Inc. | 90% | RSU 100 | No | Aon (Aon plc, Human Capital Solutions practice) |
| PTC Therapeutics, Inc. | 167% | Options 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | FW Cook |
| Sarepta Therapeutics, Inc. | 100% | RSU 50 · PSU 50 | No | FW Cook |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions practice) |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| United Therapeutics Corporation | 221% | Options 50 · PSU 50 | No | Aon Human Capital Solutions |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Joe Ciaffoni | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation Tables” · page 37. As printed: 18,501,214. Filing ↗machine: r1 · c18 · span 542781–542791 |
| 2 | Section 01, Pat Barry | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation Tables” · page 37. As printed: 4,905,744. Filing ↗machine: r12 · c18 · span 558641–558650 |
| 3 | Section 01, Christian Heidbreder | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation Tables” · page 37. As printed: 4,182,548. Filing ↗machine: r9 · c18 · span 554138–554147 |
| 4 | Section 01, Richard Simkin | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation Tables” · page 37. As printed: 4,017,316. Filing ↗machine: r17 · c18 · span 565309–565318 |
| 5 | Section 01, Ryan Preblick | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation Tables” · page 37. As printed: 3,592,393. Filing ↗machine: r6 · c18 · span 549853–549862 |
| 6 | Section 01, Jeff Burris | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation Tables” · page 37. As printed: 3,521,215. Filing ↗machine: r14 · c18 · span 561293–561302 |
| 7 | Section 01, Mark Crossley | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation Tables” · page 37. As printed: 3,185,591. Filing ↗machine: r3 · c18 · span 545524–545533 |
| 8 | Section 03, Pat Barry RSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 609109–609116 |
| 9 | Section 03, Pat Barry PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Jeff Burris PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 614352–614361 |
| 11 | Section 03, Jeff Burris PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 616612–616618 |
| 12 | Section 03, Jeff Burris RSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 612993–613000 |
| 13 | Section 03, Jeff Burris PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 615483–615490 |
| 14 | Section 03, Joe Ciaffoni RSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 590172–590181 |
| 15 | Section 03, Joe Ciaffoni PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 591509–591519 |
| 16 | Section 03, Mark Crossley PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 594911–594917 |
| 17 | Section 03, Mark Crossley RSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 593809–593815 |
| 18 | Section 03, Christian Heidbreder PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 605755–605762 |
| 19 | Section 03, Christian Heidbreder RSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 603265–603272 |
| 20 | Section 03, Christian Heidbreder PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 604624–604633 |
| 21 | Section 03, Christian Heidbreder PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 606884–606890 |
| 22 | Section 03, Ryan Preblick PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 598377–598386 |
| 23 | Section 03, Ryan Preblick RSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 597287–597294 |
| 24 | Section 03, Ryan Preblick PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 599755–599762 |
| 25 | Section 03, Ryan Preblick PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 600886–600892 |
| 26 | Section 03, Richard Simkin PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 620353–620362 |
| 27 | Section 03, Richard Simkin PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 622615–622621 |
| 28 | Section 03, Richard Simkin PSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 621486–621491 |
| 29 | Section 03, Richard Simkin RSU | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 618991–618998 |
| 30 | Section 08, David Wheadon | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 441,027. Filing ↗machine: span 321218–321225 |
| 31 | Section 08, Juliet Thompson | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 251,563. Filing ↗machine: span 320345–320352 |
| 32 | Section 08, Barbara Ryan | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 220,466. Filing ↗machine: span 317786–317793 |
| 33 | Section 08, Mark Stejbach | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 217,511. Filing ↗machine: span 319459–319466 |
| 34 | Section 08, Keith Humphreys | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 196,785. Filing ↗machine: span 314357–314364 |
| 35 | Section 08, Daniel Ninivaggi | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 186,697. Filing ↗machine: span 317001–317008 |
| 36 | Section 08, Tony Kingsley | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 140,000. Filing ↗machine: span 315241–315248 |
| 37 | Section 08, Jo LeCouilliard | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 42,035. Filing ↗machine: span 316116–316122 |
| 38 | Section 08, Peter Bains | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 39,920. Filing ↗machine: span 313515–313521 |
| 39 | Section 08, Robert Schriesheim | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 19,606. Filing ↗machine: span 318675–318681 |
| 40 | Section 08, Joe Ciaffoni | DEF 14A | 2026-03-27 | 0001104659-26-035480 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 41 | Section 06, 2026 vote | Form 8-K | 2026-05-15 | 0001625297-26-000024 | Item 5.07 · say-on-pay result. As reported: 98.55% (votes for as printed: 90,364,566). Filing ↗ |
| 42 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 43 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 44 | Section 09b board cost (computed) | Computed | — | computed | Cash 1,755,610 + equity 0 + all other 0 = 1,755,610, summed across the director compensation table rows.machine: formula: Σ = 1,755,610 |
| 45 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 46 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410 |
| 47 | BioMarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 48 | Indivior Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-03-27 | 0001104659-26-035480 | CEO total compensation as printed in Indivior Pharmaceuticals's own proxy. As printed: 18,501,214. Filing ↗machine: r1 · c18 · span 542781–542791 |
| 49 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 50 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 51 | Supernus Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 52 | Corcept Therapeutics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 53 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 54 | Neurocrine Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 55 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 56 | Pacira BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 57 | Ultragenyx Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 58 | Intra-Cellular Therapies, Inc., Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 59 | Novavax, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027328 | CEO total compensation as printed in Novavax, Inc.'s own proxy. As printed: 8,856,015. Filing ↗machine: t197 · r2 · c8 · span 944385–944394 |
| 60 | Amneal Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001308179-26-000143 | CEO total compensation as printed in Amneal Pharmaceuticals, Inc.'s own proxy. As printed: 8,691,745. Filing ↗machine: r4 · c16 · span 470587–470596 |
| 61 | Amphastar Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001297184-26-000023 | CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932 |
| 62 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗machine: t33 · span 1170878–1170887 |
| 63 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 64 | Emergent BioSolutions Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001367644-26-000033 | CEO total compensation as printed in Emergent BioSolutions Inc.'s own proxy. As printed: 5,321,147. Filing ↗machine: t155 · r3 · c15 · span 906918–906927 |
| 65 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 66 | Section 10a, Intra-Cellular Therapies, Inc. reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 67 | Section 10a, Emergent BioSolutions Inc. reciprocity | DEF 14A | — | 0001367644-26-000033 | Emergent BioSolutions Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 68 | Section 10a, Supernus Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 69 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 70 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 71 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 72 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation's most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 73 | Section 10a, Novavax, Inc. reciprocity | DEF 14A | — | 0001628280-26-027328 | Novavax, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 74 | Section 10a, Neurocrine Biosciences, Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 75 | Section 10a, Amphastar Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001297184-26-000023 | Amphastar Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 76 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 77 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation's most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 78 | Section 10a, BioMarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 79 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 80 | Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |
| 81 | Section 10a, Pacira BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Indivior Pharmaceuticals. Filing ↗ |